call Toll Free (US/Canada) : +1 866 658 6826 | call +1 425 320 4776 | call (UK) : +44 1865 60 0662 | email info(@)blueweaveconsulting.com
Home | About Us | Career | Services | Blog | Contact Us
Blueweave
Multiple Myeloma Market
Inquire Before Buying Request for Sample

Multiple Myeloma Market

Home Chemicals And Materials Multiple Myeloma Market

SPECIAL OFFER : 25% Super Discount For All !

Multiple Myeloma Market - Global Size, Share, Trend Analysis, Opportunity and Forecast Report, 2019–2029, Segmented By Type (Smoldering (indolent) Multiple Myeloma, Active (Symptomatic) Multiple Myeloma); By Treatment (Chemotherapy, Targeted Therapy, Immunomodulatory Drugs, Steroids, Bone-Modifying Drugs, Immunotherapy, Bone Marrow/Stem Cell Transplantation, Radiation Therapy, Surgery); By Diagnosis (Blood & Urine Tests, X-ray, Magnetic Resonance Imaging (MRI), Computed Tomography (CT/CAT) Scan, Positron Emission Tomography (PET)/ PET-CT Scan, Bone Marrow Aspiration & Biopsy, Fat Pad Aspirate, Biomarker Testing of the Tumor); By Region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa)

  • Published Date: October 2023
  • Report ID: BWC23812
  • Available Format: PDF
  • Page: 400

Report Overview

The rising incidence of multiple myeloma globally and increasing advancements in targeted drugs are projected to propel the expansion of the global multiple myeloma market during the forecast period between 2023 and 2029

Global Multiple Myeloma Market - Industry Trends & Forecast Report, 2029

Global multiple myeloma market size was estimated at USD 21.46 billion in 2022. During the forecast period between 2023 and 2029, the size of global multiple myeloma market is projected to grow at a CAGR of 5.39% reaching a value of USD 29.4 billion by 2029. Major growth drivers for the global multiple myeloma market include an increasing adoption of microRNA therapies. These innovative therapeutic approaches harness the potential of microRNAs to modulate gene expression and regulate various cellular processes. The development of targeted microRNA therapies offers the prospect of more precise and individualized treatments for multiple myeloma. Also, the rise of advanced biomedicine platforms plays a pivotal role in driving the growth of the multiple myeloma market. These platforms encompass a diverse array of technologies and methodologies that facilitate the comprehension of the molecular underpinnings of the disease, the discovery of novel therapeutic targets, and the formulation of more efficacious treatment strategies. By leveraging these advanced platforms, researchers and healthcare practitioners can gain deeper insights into Multiple Myeloma and advance the development of groundbreaking therapeutic interventions.

Multiple Myeloma Market

Global Multiple Myeloma Market – Overview

The global multiple myeloma market refers to the collective economic and commercial landscape associated with the diagnosis, treatment, and management of multiple myeloma, a type of cancer that affects plasma cells in the bone marrow. This market encompasses various pharmaceutical products, medical devices, diagnostic tools, research initiatives, and healthcare services related to multiple myeloma. It involves the production, distribution, and consumption of drugs, therapies, and technologies aimed at preventing, controlling, or curing multiple myeloma, as well as efforts to enhance patient care, improve outcomes, and advance scientific understanding of the disease. The global multiple myeloma market is influenced by factors such as medical advancements, regulatory policies, research and development activities, and the demand for innovative treatment approaches in the global healthcare industry.

Global Multiple Myeloma Market

Growth Drivers

Rising Incidence of Multiple Myeloma Globally

The relentless global rise in multiple myeloma diagnoses fuels the exponential growth of the global multiple myeloma market. This surge not only underscores the pressing need for improved treatments but also propels proactive measures within the pharmaceutical and healthcare sectors. The escalating incidence drives intensified research, yielding innovative therapies, cutting-edge pharmaceuticals, and groundbreaking treatment approaches. Pharmaceutical enterprises are investing significantly in tailored medications for this intricate malignancy, while healthcare providers are diligently working to enhance patient access to these transformative innovations. These collective efforts synergize with the alarming statistics: an estimated 35,730 diagnoses in the United States in 2023 and approximately 176,404 global cases diagnosed in 2020. These figures underscore the substantial burden this disease places on both a national and global scale, emphasizing the urgent need for advanced targeted drugs and therapies within the global multiple myeloma market.

Restraints

High Treatment Costs

The global multiple myeloma market encounters a significant growth constraint in the form of high treatment costs. The complex nature of multiple myeloma necessitates multifaceted treatment approaches, including targeted drugs, immunotherapies, and stem cell transplants, all of which can be financially burdensome for patients and healthcare systems. These elevated treatment expenses pose challenges in terms of patient access to cutting-edge therapies and often result in financial strain on individuals and their families. Furthermore, the financial burden of multiple myeloma treatment can limit market expansion by curbing investment in research and development. Mitigating the cost barriers while maintaining treatment quality is essential for realizing the full potential of the global multiple myeloma market.

Impact of COVID-19 on Global Multiple Myeloma Market

COVID-19 pandemic adversely affected the global multiple myeloma market. The crisis disrupted supply chains, delayed clinical trials, and redirected healthcare resources toward managing the pandemic. Multiple myeloma patients faced challenges in accessing treatments and medical care due to overwhelmed healthcare systems and safety concerns. Telemedicine gained prominence for consultations, but in-person treatments and clinical assessments were often delayed. Additionally, financial strains on healthcare systems affected research funding and hindered the development of new therapies. Despite these setbacks, the pandemic accelerated digital health adoption and emphasized the importance of resilient healthcare systems. The global multiple myeloma market is adapting to these challenges, but its growth trajectory was undoubtedly impacted by the pandemic.

Global Multiple Myeloma Market

Segmental Coverage

Global Multiple Myeloma Market – By Type

Based on type, the global multiple myeloma market is bifurcated into Smoldering (indolent) Multiple Myeloma and Active (symptomatic) Multiple Myeloma segments. The active (symptomatic) multiple myeloma segment is expected to hold a higher share in the global multiple myeloma market during the forecast period by type. This is primarily because active multiple myeloma requires immediate and often more aggressive medical intervention, including chemotherapy, targeted drugs, and stem cell transplants, making it a higher priority for treatment compared to asymptomatic myeloma. Additionally, the increasing incidence of symptomatic cases underscores the growing demand for advanced treatments, further driving the prominence of the active myeloma segment in the market.

Advanced Ceramics Market Share

Global Multiple Myeloma Market – By Treatment

On the basis of treatment, the global multiple myeloma market is divided into Chemotherapy, Targeted Therapy, Immunomodulatory Drugs, Steroids, Bone-Modifying Drugs, Immunotherapy, Bone Marrow/Stem Cell Transplantation, Radiation Therapy, and Surgery. The immunomodulatory drugs segment holds the highest share in the global multiple myeloma market by treatment. The prominence of immunomodulators in the market is attributed to various factors, including the increasing prevalence of multiple myeloma and the rising demand for these drugs. Immunomodulators play a crucial role in modifying or delaying the progression of autoimmune, inflammatory, and cancerous conditions, with notable drugs like Thalomid, Revlimid, and pomalyst being used for multiple myeloma treatment. The growing incidence of multiple myeloma is a primary driver, with lenalidomide, an immunomodulatory drug, demonstrating improved outcomes in studies, enhancing progression-free survival, response depth, and overall survival rates. This is expected to boost its adoption among patients and stimulate market growth. Also, increased research and development efforts and a rising number of drug approvals further contribute to market expansion.

Global Multiple Myeloma Market – By Diagnosis

Based on diagnosis, the global multiple myeloma market is divided into Blood and urine tests, X-ray, Magnetic Resonance Imaging (MRI), Computed Tomography (CT or CAT) Scan, Positron Emission Tomography (PET) or PET-CT Scan, Bone Marrow Aspiration & Biopsy, Fat Pad Aspirate, and Biomarker Testing of the tumor segments.

Global Multiple Myeloma Market – By Region

The in-depth research report on the global multiple myeloma market covers various country-specific markets across five major regions: North America, Europe, Asia Pacific (APAC), Latin America, and Middle East and Africa. North America is poised to play a significant role in the multiple myeloma market during the forecast period, driven by several factors. These include the growing incidence of multiple myeloma, increased efforts by pharmaceutical companies in developing effective treatments, rising healthcare expenditure, substantial healthcare investments, and the presence of key market players in the region. The rising prevalence of multiple myeloma is a primary catalyst for market expansion. Also, according to ACS, the lifetime risk of developing multiple myeloma in the U.S. stands at 1 in 132 (0.76%). Similarly, in Canada, the Canadian Cancer Society estimated around 4,000 new cases of multiple myeloma (MM) for 2022. This substantial disease burden underscores the demand for effective treatments, thereby fueling market growth. Notably, the introduction of various awareness programs and campaigns aimed at increasing public understanding of multiple myeloma is contributing to market expansion. These initiatives are expected to enhance public knowledge about the condition and further drive market growth during the forecast period

Competitive Landscape

Major players operating in the global multiple myeloma market include Sanofi, Pfizer Inc., GlaxoSmithKline plc, Novartis AG, Bayer AG, Eli Lilly and Company, Merck & Co., Inc., AstraZeneca, Bristol-Myers Squibb Company, AbbVie Inc., Teva Pharmaceutical Industries Ltd, ONO Pharmaceutical Co., Ltd, Takeda Pharmaceutical Company Ltd, and Roche Group. To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.

Recent Developments

  • In December 2022 - Kite, a subsidiary of Gilead, established a global strategic collaboration with Aecellex for the collaborative advancement and marketing of CART-ddBCMA, a T-cell therapy designed for the treatment of individuals with relapsed or refractory multiple myeloma. Furthermore, the CART-ddBCMA therapy is currently undergoing Phase I clinical evaluation. As part of this partnership, Arcellx will provide an initial payment of USD 225 million to Kite.

Scope of the Report

Attributes

Details

Years Considered

Historical Data – 2019–2022

Base Year – 2022

Estimated Year – 2023

Forecast Period – 2023–2029

Facts Covered

Revenue in USD Billion

Market Coverage

North America, Europe, Asia Pacific, Latin America, Middle East and Africa 

Product/ Service Segmentation

Type, Treatment, Diagnosis, Region

Key Players

Sanofi, Pfizer Inc., GlaxoSmithKline plc, Novartis AG, Bayer AG, Eli Lilly and Company, Merck & Co., Inc., AstraZeneca, Bristol-Myers Squibb Company, AbbVie Inc., Teva Pharmaceutical Industries Ltd, ONO Pharmaceutical Co., Ltd, Takeda Pharmaceutical Company Ltd, Roche Group.

 

By Type

  • Smoldering (indolent) Multiple Myeloma

  • Active (symptomatic) Multiple Myeloma

By Treatment

  • Chemotherapy

  • Targeted Therapy

  • Immunomodulatory Drugs

  • Steroids

  • Bone-modifying Drugs

  • Immunotherapy

  • Bone Marrow/Stem Cell Transplantation

  • Radiation Therapy

  • Surgery

By Diagnosis

  • Blood & Urine Tests

  • X-ray

  • Magnetic Resonance Imaging (MRI)

  • Computed Tomography (CT/CAT) Scan

  • Positron Emission Tomography (PET)/PET-CT Scan

  • Bone marrow Aspiration & Biopsy

  • Fat Pad Aspirate

  • Biomarker Testing of the Tumor

By Region

  • North America

  • Europe

  • Asia Pacific

  • Latin America

  • Middle East and Africa

  1. Research Framework
    1. Research Objective
    2. Product Overview
    3. Market Segmentation
  2. Executive Summary
  3.  Global Multiple Myeloma Market Insights
    1. Industry Value Chain Analysis
    2. DROC Analysis
      1. Growth Drivers
        1. The rising incidence of Multiple Myeloma globally
        2. Advancements in targeted drugs
      2. Restraints
        1. High treatment costs
        2. Stringent regulatory requirements
      3. Opportunities
        1. Emerging markets
        2. Personalized medicine
      4. Challenges
        1. Competition
        2. Drug resistance
    3. Technological Advancements/Recent Developments
    4. Regulatory Framework
    5. Porter’s Five Forces Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of New Entrants
      4. Threat of Substitutes
      5. Intensity of Rivalry
  4.  Global Multiple Myeloma Market Overview
    1. Market Size & Forecast, 2019–2029
      1. By Value (USD Billion)
    2. Market Share and Forecast
      1. By Type
        1. Smoldering (indolent) Multiple Myeloma
        2. Active (symptomatic) Multiple Myeloma
      2. By Treatment
        1. Chemotherapy
        2. Targeted Therapy
        3. Immunomodulatory Drugs
        4. Steroids
        5. Bone-modifying Drugs
        6. Immunotherapy
        7. Bone Marrow/Stem Cell Transplantation
        8. Radiation Therapy
        9. Surgery
        10. Others
      3. By Diagnosis
        1. Blood & Urine Tests
        2. X-ray
        3. Magnetic Resonance Imaging (MRI)
        4. Computed Tomography (CT or CAT) Scan
        5. Positron Emission Tomography (PET) or PET-CT Scan
        6. Bone Marrow Aspiration and Biopsy
        7. Fat Pad Aspirate
        8. Biomarker Testing of the Tumor
        9. Others
      4. By Region
        1. North America
        2. Europe
        3. Asia Pacific (APAC)
        4. Latin America (LATAM)
        5. Middle East and Africa (MEA)
  5. North America Multiple Myeloma Market
    1. Market Size & Forecast, 2019–2029
      1. By Value (USD Billion)
    2. Market Share & Forecast
      1. By Type
      2. By Treatment
      3. By Diagnosis
      4. By Country
        1. United States
          1. By Type
          2. By Treatment
          3. By Diagnosis
        2. Canada
          1. By Type
          2. By Treatment
          3. By Diagnosis
  6. Europe Multiple Myeloma Market
    1. Market Size & Forecast, 2019–2029
      1. By Value (USD Billion)
    2. Market Share & Forecast
      1. By Type
      2. By Treatment
      3. By Diagnosis
      4. By Country
        1. Germany
          1. By Type
          2. By Treatment
          3. By Diagnosis
        2. United Kingdom
          1. By Type
          2. By Treatment
          3. By Diagnosis
        3. Italy
          1. By Type
          2. By Treatment
          3. By Diagnosis
        4. France
          1. By Type
          2. By Treatment
          3. By Diagnosis
        5. Spain
          1. By Type
          2. By Treatment
          3. By Diagnosis
        6. Belgium
          1. By Type
          2. By Treatment
          3. By Diagnosis
        7. Russia
          1. By Type
          2. By Treatment
          3. By Diagnosis
        8. The Netherlands
          1. By Type
          2. By Treatment
          3. By Diagnosis
        9. Rest of Europe
          1. By Type
          2. By Treatment
          3. By Diagnosis
  7. Asia-Pacific Multiple Myeloma Market
    1. Market Size & Forecast, 2019–2029
      1. By Value (USD Billion)
    2. Market Share & Forecast
      1. By Type
      2. By Treatment
      3. By Diagnosis
      4. By Country
        1. China
          1. By Type
          2. By Treatment
          3. By Diagnosis
        2. India
          1. By Type
          2. By Treatment
          3. By Diagnosis
        3. Japan
          1. By Type
          2. By Treatment
          3. By Diagnosis
        4. South Korea
          1. By Type
          2. By Treatment
          3. By Diagnosis
        5. Australia & New Zealand
          1. By Type
          2. By Treatment
          3. By Diagnosis
        6. Indonesia
          1. By Type
          2. By Treatment
          3. By Diagnosis
        7. Malaysia
          1. By Type
          2. By Treatment
          3. By Diagnosis
        8. Singapore
          1. By Type
          2. By Treatment
          3. By Diagnosis
        9. Vietnam
          1. By Type
          2. By Treatment
          3. By Diagnosis
        10. Rest of APAC
          1. By Type
          2. By Treatment
          3. By Diagnosis
  8. Latin America Multiple Myeloma Market
    1. Market Size & Forecast, 2019–2029
      1. By Value (USD Billion)
    2. Market Share & Forecast
      1. By Type
      2. By Treatment
      3. By Diagnosis
      4. By Country
        1. Brazil
          1. By Type
          2. By Treatment
          3. By Diagnosis
        2. Mexico
          1. By Type
          2. By Treatment
          3. By Diagnosis
        3. Argentina
          1. By Type
          2. By Treatment
          3. By Diagnosis
        4. Peru
          1. By Type
          2. By Treatment
          3. By Diagnosis
        5. Rest of LATAM
          1. By Type
          2. By Treatment
          3. By Diagnosis
  9. Middle East & Africa Multiple Myeloma Market
    1. Market Size & Forecast, 2019–2029
      1. By Value (USD Billion)
    2. Market Share & Forecast
      1. By Type
      2. By Treatment
      3. By Diagnosis
      4. By Country
        1. Saudi Arabia
          1. By Type
          2. By Treatment
          3. By Diagnosis
        2. UAE
          1. By Type
          2. By Treatment
          3. By Diagnosis
        3. Qatar
          1. By Type
          2. By Treatment
          3. By Diagnosis
        4. Kuwait
          1. By Type
          2. By Treatment
          3. By Diagnosis
        5. South Africa
          1. By Type
          2. By Treatment
          3. By Diagnosis
        6. Nigeria
          1. By Type
          2. By Treatment
          3. By Diagnosis
        7. Algeria
          1. By Type
          2. By Treatment
          3. By Diagnosis
        8. Rest of MEA
          1. By Type
          2. By Treatment
          3. By Diagnosis
  10. Competitive Landscape
    1. List of Key Players and Their Offerings
    2. Global Multiple Myeloma Market Share Analysis, 2022
    3. Competitive Benchmarking, By Operating Parameters
    4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)
  11. Impact of Covid-19 on Global Multiple Myeloma Market
  12. Company Profile (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, SWOT Analysis)
    1. Sanofi
    2. Pfizer Inc.
    3. GlaxoSmithKline plc
    4. Novartis AG
    5. Bayer AG
    6. Eli Lilly and Company
    7. Merck & Co., Inc.
    8. AstraZeneca
    9. Bristol-Myers Squibb Company
    10. AbbVie Inc.
    11. Teva Pharmaceutical Industries Ltd
    12. ONO Pharmaceutical Co., Ltd
    13. Takeda Pharmaceutical Company Ltd
    14. Roche Group
    15. Other Prominent Players
  13. Key Strategic Recommendations
  14. Research Methodology
    1.    Qualitative Research
      1.  Primary & Secondary Research
    2.    Quantitative Research
    3.    Market Breakdown & Data Triangulation
      1.  Secondary Research
      2.  Primary Research
    4.    Breakdown of Primary Research Respondents, By Region
    5.    Assumptions & Limitations

*Financial information of non-listed companies can be provided as per availability.

**The segmentation and the companies are subject to modifications based on in-depth secondary research for the final deliverable

 

Figures

Figure 1       Global Multiple Myeloma Segmentation

Figure 2       Global Multiple Myeloma Market Value Chain Analysis

Figure 3       Company Market Share Analysis, 2022

Figure 4       Global Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029

Figure 5       Global Multiple Myeloma Market Share, By Type, By Value, 2019–2029

Figure 6       Global Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029

Figure 7       Global Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029

Figure 8       Global Multiple Myeloma Market Share, By Region, By Value, 2019–2029

Figure 9       North America Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029

Figure 10     North America Multiple Myeloma Market Share, By Type, By Value, 2019–2029

Figure 11     North America Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029

Figure 12     North America Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029

Figure 13     North America Multiple Myeloma Market Share, By Country, By Value, 2019–2029

Figure 14     United States Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029

Figure 15     United States Multiple Myeloma Market Share, By Type, By Value, 2019–2029

Figure 16     United States Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029

Figure 17     United States Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029

Figure 18     Canada Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029

Figure 19     Canada Multiple Myeloma Market Share, By Type, By Value, 2019–2029

Figure 20     Canada Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029

Figure 21     Canada Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029

Figure 22     Europe Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029

Figure 23     Europe Multiple Myeloma Market Share, By Type, By Value, 2019–2029

Figure 24     Europe Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029

Figure 25     Europe Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029

Figure 26     Europe Multiple Myeloma Market Share, By Country, By Value, 2019–2029

Figure 27     Germany Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029

Figure 28     Germany Multiple Myeloma Market Share, By Type, By Value, 2019–2029

Figure 29     Germany Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029

Figure 30     Germany Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029

Figure 31     United Kingdom Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029

Figure 32     United Kingdom Multiple Myeloma Market Share, By Type, By Value, 2019–2029

Figure 33     United Kingdom Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029

Figure 34     United Kingdom Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029

Figure 35     Italy Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029

Figure 36     Italy Multiple Myeloma Market Share, By Type, By Value, 2019–2029

Figure 37     Italy Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029

Figure 38     Italy Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029

Figure 39     France Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029

Figure 40     France Multiple Myeloma Market Share, By Type, By Value, 2019–2029

Figure 41     France Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029

Figure 42     France Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029

Figure 43     Spain Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029

Figure 44     Spain Multiple Myeloma Market Share, By Type, By Value, 2019–2029

Figure 45     Spain Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029

Figure 46     Spain Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029

Figure 47     Belgium Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029

Figure 48     Belgium Multiple Myeloma Market Share, By Type, By Value, 2019–2029

Figure 49     Belgium Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029

Figure 50     Belgium Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029

Figure 51     Russia Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029

Figure 52     Russia Multiple Myeloma Market Share, By Type, By Value, 2019–2029

Figure 53     Russia Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029

Figure 54     Russia Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029

Figure 55     The Netherlands Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029

Figure 56     The Netherlands Multiple Myeloma Market Share, By Type, By Value, 2019–2029

Figure 57     The Netherlands Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029

Figure 58     The Netherlands Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029

Figure 59     Rest of Europe Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029

Figure 60     Rest of Europe Multiple Myeloma Market Share, By Type, By Value, 2019–2029

Figure 61     Rest of Europe Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029

Figure 62     Rest of Europe Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029

Figure 63     Asia-Pacific Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029

Figure 64     Asia-Pacific Multiple Myeloma Market Share, By Type, By Value, 2019–2029

Figure 65     Asia-Pacific Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029

Figure 66     Asia-Pacific Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029

Figure 67     Asia-Pacific Multiple Myeloma Market Share, By Country, By Value, 2019–2029

Figure 68     China Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029

Figure 69     China Multiple Myeloma Market Share, By Type, By Value, 2019–2029

Figure 70     China Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029

Figure 71     China Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029

Figure 72     India Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029

Figure 73     India Multiple Myeloma Market Share, By Type, By Value, 2019–2029

Figure 74     India Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029

Figure 75     India Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029

Figure 76     Japan Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029

Figure 77     Japan Multiple Myeloma Market Share, By Type, By Value, 2019–2029

Figure 78     Japan Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029

Figure 79     Japan Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029

Figure 80     South Korea Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029

Figure 81     South Korea Multiple Myeloma Market Share, By Type, By Value, 2019–2029

Figure 82     South Korea Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029

Figure 83     South Korea Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029

Figure 84     Australia & New Zealand Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029

Figure 85     Australia & New Zealand Multiple Myeloma Market Share, By Type, By Value, 2019–2029

Figure 86     Australia & New Zealand Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029

Figure 87     Australia & New Zealand Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029

Figure 88     Indonesia Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029

Figure 89     Indonesia Multiple Myeloma Market Share, By Type, By Value, 2019–2029

Figure 90     Indonesia Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029

Figure 91     Indonesia Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029

Figure 92     Malaysia Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029

Figure 93     Malaysia Multiple Myeloma Market Share, By Type, By Value, 2019–2029

Figure 94     Malaysia Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029

Figure 95     Malaysia Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029

Figure 96     Singapore Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029

Figure 97     Singapore Multiple Myeloma Market Share, By Type, By Value, 2019–2029

Figure 98     Singapore Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029

Figure 99     Singapore Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029

Figure 100   Vietnam Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029

Figure 101   Vietnam Multiple Myeloma Market Share, By Type, By Value, 2019–2029

Figure 102   Vietnam Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029

Figure 103   Vietnam Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029

Figure 104   Rest of APAC Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029

Figure 105   Rest of APAC Multiple Myeloma Market Share, By Type, By Value, 2019–2029

Figure 106   Rest of APAC Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029

Figure 107   Rest of APAC Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029

Figure 108   Latin America Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029

Figure 109   Latin America Multiple Myeloma Market Share, By Type, By Value, 2019–2029

Figure 110   Latin America Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029

Figure 111   Latin America Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029

Figure 112   Latin America Multiple Myeloma Market Share, By Country, By Value, 2019–2029

Figure 113   Brazil Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029

Figure 114   Brazil Multiple Myeloma Market Share, By Type, By Value, 2019–2029

Figure 115   Brazil Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029

Figure 116   Brazil Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029

Figure 117   Mexico Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029

Figure 118   Mexico Multiple Myeloma Market Share, By Type, By Value, 2019–2029

Figure 119   Mexico Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029

Figure 120   Mexico Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029

Figure 121   Argentina Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029

Figure 122   Argentina Multiple Myeloma Market Share, By Type, By Value, 2019–2029

Figure 123   Argentina Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029

Figure 124   Argentina Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029

Figure 125   Peru Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029

Figure 126   Peru Multiple Myeloma Market Share, By Type, By Value, 2019–2029

Figure 127   Peru Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029

Figure 128   Peru Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029

Figure 129   Rest of LATAM Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029

Figure 130   Rest of LATAM Multiple Myeloma Market Share, By Type, By Value, 2019–2029

Figure 131   Rest of LATAM Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029

Figure 132   Rest of LATAM Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029

Figure 133   Middle East & Africa Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029

Figure 134   Middle East & Africa Multiple Myeloma Market Share, By Type, By Value, 2019–2029

Figure 135   Middle East & Africa Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029

Figure 136   Middle East & Africa Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029

Figure 137   Middle East & Africa Multiple Myeloma Market Share, By Country, By Value, 2019–2029

Figure 138   Saudi Arabia Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029

Figure 139   Saudi Arabia Multiple Myeloma Market Share, By Type, By Value, 2019–2029

Figure 140   Saudi Arabia Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029

Figure 141   Saudi Arabia Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029

Figure 142   UAE Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029

Figure 143   UAE Multiple Myeloma Market Share, By Type, By Value, 2019–2029

Figure 144   UAE Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029

Figure 145   UAE Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029

Figure 146   Qatar Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029

Figure 147   Qatar Multiple Myeloma Market Share, By Type, By Value, 2019–2029

Figure 148   Qatar Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029

Figure 149   Qatar Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029

Figure 150   Kuwait Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029

Figure 151   Kuwait Multiple Myeloma Market Share, By Type, By Value, 2019–2029

Figure 152   Kuwait Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029

Figure 153   Kuwait Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029

Figure 154   South Africa Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029

Figure 155   South Africa Multiple Myeloma Market Share, By Type, By Value, 2019–2029

Figure 156   South Africa Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029

Figure 157   South Africa Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029

Figure 158   Nigeria Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029

Figure 159   Nigeria Multiple Myeloma Market Share, By Type, By Value, 2019–2029

Figure 160   Nigeria Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029

Figure 161   Nigeria Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029

Figure 162   Algeria Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029

Figure 163   Algeria Multiple Myeloma Market Share, By Type, By Value, 2019–2029

Figure 164   Algeria Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029

Figure 165   Algeria Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029

Figure 166   Rest of MEA Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029

Figure 167   Rest of MEA Multiple Myeloma Market Share, By Type, By Value, 2019–2029

Figure 168   Rest of MEA Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029

Figure 169   Rest of MEA Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029

 

List of Tables

Table 1        Global Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029

Table 2 Global Multiple Myeloma Market Share, By Type, By Value, 2019–2029

Table 3 Global Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029

Table 4 Global Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029

Table 5 Global Multiple Myeloma Market Share, By Region, By Value, 2019–2029

Table 6 North America Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029

Table 7 North America Multiple Myeloma Market Share, By Type, By Value, 2019–2029

Table 8 North America Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029

Table 9 North America Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029

Table 10      North America Multiple Myeloma Market Share, By Country, By Value, 2019–2029

Table 11      United States Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029

Table 12      United States Multiple Myeloma Market Share, By Type, By Value, 2019–2029

Table 13      United States Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029

Table 14      United States Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029

Table 15      Canada Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029

Table 16      Canada Multiple Myeloma Market Share, By Type, By Value, 2019–2029

Table 17      Canada Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029

Table 18      Canada Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029

Table 19      Europe Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029

Table 20      Europe Multiple Myeloma Market Share, By Type, By Value, 2019–2029

Table 21      Europe Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029

Table 22      Europe Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029

Table 23      Europe Multiple Myeloma Market Share, By Country, By Value, 2019–2029

Table 24      Germany Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029

Table 25      Germany Multiple Myeloma Market Share, By Type, By Value, 2019–2029

Table 26      Germany Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029

Table 27      Germany Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029

Table 28      United Kingdom Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029

Table 29      United Kingdom Multiple Myeloma Market Share, By Type, By Value, 2019–2029

Table 30      United Kingdom Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029

Table 31      United Kingdom Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029

Table 32      Italy Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029

Table 33      Italy Multiple Myeloma Market Share, By Type, By Value, 2019–2029

Table 34      Italy Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029

Table 35      Italy Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029

Table 36      France Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029

Table 37      France Multiple Myeloma Market Share, By Type, By Value, 2019–2029

Table 38      France Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029

Table 39      France Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029

Table 40      Spain Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029

Table 41      Spain Multiple Myeloma Market Share, By Type, By Value, 2019–2029

Table 42      Spain Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029

Table 43      Spain Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029

Table 44      Belgium Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029

Table 45      Belgium Multiple Myeloma Market Share, By Type, By Value, 2019–2029

Table 46      Belgium Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029

Table 47      Belgium Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029

Table 48      Russia Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029

Table 49      Russia Multiple Myeloma Market Share, By Type, By Value, 2019–2029

Table 50      Russia Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029

Table 51      Russia Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029

Table 52      The Netherlands Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029

Table 53      The Netherlands Multiple Myeloma Market Share, By Type, By Value, 2019–2029

Table 54      The Netherlands Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029

Table 55      The Netherlands Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029

Table 56      Rest of Europe Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029

Table 57      Rest of Europe Multiple Myeloma Market Share, By Type, By Value, 2019–2029

Table 58      Rest of Europe Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029

Table 59      Rest of Europe Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029

Table 60      Asia-Pacific Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029

Table 61      Asia-Pacific Multiple Myeloma Market Share, By Type, By Value, 2019–2029

Table 62      Asia-Pacific Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029

Table 63      Asia-Pacific Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029

Table 64      Asia-Pacific Multiple Myeloma Market Share, By Country, By Value, 2019–2029

Table 65      China Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029

Table 66      China Multiple Myeloma Market Share, By Type, By Value, 2019–2029

Table 67      China Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029

Table 68      China Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029

Table 69      India Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029

Table 70      India Multiple Myeloma Market Share, By Type, By Value, 2019–2029

Table 71      India Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029

Table 72      India Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029

Table 73      Japan Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029

Table 74      Japan Multiple Myeloma Market Share, By Type, By Value, 2019–2029

Table 75      Japan Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029

Table 76      Japan Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029

Table 77      South Korea Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029

Table 78      South Korea Multiple Myeloma Market Share, By Type, By Value, 2019–2029

Table 79      South Korea Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029

Table 80      South Korea Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029

Table 81      Australia & New Zealand Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029

Table 82      Australia & New Zealand Multiple Myeloma Market Share, By Type, By Value, 2019–2029

Table 83      Australia & New Zealand Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029

Table 84      Australia & New Zealand Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029

Table 85      Indonesia Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029

Table 86      Indonesia Multiple Myeloma Market Share, By Type, By Value, 2019–2029

Table 87      Indonesia Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029

Table 88      Indonesia Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029

Table 89      Malaysia Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029

Table 90      Malaysia Multiple Myeloma Market Share, By Type, By Value, 2019–2029

Table 91      Malaysia Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029

Table 92      Malaysia Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029

Table 93      Singapore Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029

Table 94      Singapore Multiple Myeloma Market Share, By Type, By Value, 2019–2029

Table 95      Singapore Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029

Table 96      Singapore Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029

Table 97      Vietnam Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029

Table 98      Vietnam Multiple Myeloma Market Share, By Type, By Value, 2019–2029

Table 99      Vietnam Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029

Table 100    Vietnam Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029

Table 101    Rest of APAC Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029

Table 102    Rest of APAC Multiple Myeloma Market Share, By Type, By Value, 2019–2029

Table 103    Rest of APAC Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029

Table 104    Rest of APAC Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029

Table 105    Latin America Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029

Table 106    Latin America Multiple Myeloma Market Share, By Type, By Value, 2019–2029

Table 107    Latin America Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029

Table 108    Latin America Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029

Table 109    Latin America Multiple Myeloma Market Share, By Country, By Value, 2019–2029

Table 110    Brazil Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029

Table 111    Brazil Multiple Myeloma Market Share, By Type, By Value, 2019–2029

Table 112    Brazil Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029

Table 113    Brazil Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029

Table 114    Mexico Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029

Table 115    Mexico Multiple Myeloma Market Share, By Type, By Value, 2019–2029

Table 116    Mexico Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029

Table 117    Mexico Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029

Table 118    Argentina Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029

Table 119    Argentina Multiple Myeloma Market Share, By Type, By Value, 2019–2029

Table 120    Argentina Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029

Table 121    Argentina Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029

Table 122    Peru Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029

Table 123    Peru Multiple Myeloma Market Share, By Type, By Value, 2019–2029

Table 124    Peru Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029

Table 125    Peru Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029

Table 126    Rest of LATAM Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029

Table 127    Rest of LATAM Multiple Myeloma Market Share, By Type, By Value, 2019–2029

Table 128    Rest of LATAM Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029

Table 129    Rest of LATAM Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029

Table 130    Middle East & Africa Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029

Table 131    Middle East & Africa Multiple Myeloma Market Share, By Type, By Value, 2019–2029

Table 132    Middle East & Africa Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029

Table 133    Middle East & Africa Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029

Table 134    Middle East & Africa Multiple Myeloma Market Share, By Country, By Value, 2019–2029

Table 135    Saudi Arabia Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029

Table 136    Saudi Arabia Multiple Myeloma Market Share, By Type, By Value, 2019–2029

Table 137    Saudi Arabia Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029

Table 138    Saudi Arabia Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029

Table 139    UAE Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029

Table 140    UAE Multiple Myeloma Market Share, By Type, By Value, 2019–2029

Table 141    UAE Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029

Table 142    UAE Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029

Table 143    Qatar Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029

Table 144    Qatar Multiple Myeloma Market Share, By Type, By Value, 2019–2029

Table 145    Qatar Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029

Table 146    Qatar Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029

Table 147    Kuwait Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029

Table 148    Kuwait Multiple Myeloma Market Share, By Type, By Value, 2019–2029

Table 149    Kuwait Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029

Table 150    Kuwait Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029

Table 151    South Africa Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029

Table 152    South Africa Multiple Myeloma Market Share, By Type, By Value, 2019–2029

Table 153    South Africa Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029

Table 154    South Africa Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029

Table 155    Nigeria Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029

Table 156    Nigeria Multiple Myeloma Market Share, By Type, By Value, 2019–2029

Table 157    Nigeria Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029

Table 158    Nigeria Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029

Table 159    Algeria Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029

Table 160    Algeria Multiple Myeloma Market Share, By Type, By Value, 2019–2029

Table 161    Algeria Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029

Table 162    Algeria Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029

Table 163    Rest of MEA Multiple Myeloma Market Size, By Value (USD Billion), 2019–2029

Table 164    Rest of MEA Multiple Myeloma Market Share, By Type, By Value, 2019–2029

Table 165    Rest of MEA Multiple Myeloma Market Share, By Treatment, By Value, 2019–2029

Table 166    Rest of MEA Multiple Myeloma Market Share, By Diagnosis, By Value, 2019–2029

Table 167    Sanofi  Company Overview

Table 168    Sanofi  Financial Overview

Table 169    Pfizer Inc. Company Overview

Table 170    Pfizer Inc. Financial Overview

Table 171    GlaxoSmithKline plc  Company Overview

Table 172    GlaxoSmithKline plc  Financial Overview

Table 173    Novartis AG  Company Overview

Table 174    Novartis AG  Financial Overview

Table 175    Bayer AG  Company Overview

Table 176    Bayer AG  Financial Overview

Table 177    Eli Lilly and Company Overview

Table 178    Eli Lilly and Company Financial Overview

Table 179    Merck & Co., Inc. Company Overview

Table 180    Merck & Co., Inc. Financial Overview

Table 181    AstraZeneca Company Overview

Table 182    AstraZeneca Financial Overview

Table 183    Bristol-Myers Squibb Company Overview

Table 184    Bristol-Myers Squibb Company Financial Overview

Table 185    AbbVie Inc. Company Overview

Table 186    AbbVie Inc. Financial Overview

Table 187    Teva Pharmaceutical Industries Ltd. Company Overview

Table 188    Teva Pharmaceutical Industries Ltd. Financial Overview

Table 189    ONO Pharmaceutical Co., Ltd. Company Overview

Table 190    ONO Pharmaceutical Co., Ltd. Financial Overview

Table 191    Takeda Pharmaceutical Company Ltd. Company Overview

Table 192    Takeda Pharmaceutical Company Ltd. Financial Overview

Table 193    Roche Group Company Overview

Table 194    Roche Group Financial Overview

Market Segmentation

No data available
No data available

To request a free sample copy of this report, please complete the form below.

We value your investment and offer free customization with every report to fulfil your exact research needs.

This website is secure and your personal details are safe.

Frequently Asked Questions (FAQs):

Ans: Global Multiple Myeloma Market size was estimated at USD 21.46 billion in 2022.
Ans: Major factors driving the growth of the Global Multiple Myeloma Market include the rising incidence of multiple myeloma globally and increasing advancements in targeted drugs.
Ans: Key players in the Global Multiple Myeloma Market include Sanofi, Pfizer Inc., GlaxoSmithKline plc, Novartis AG, Bayer AG, Eli Lilly and Company, Merck & Co., Inc., AstraZeneca, Bristol-Myers Squibb Company, AbbVie Inc., Teva Pharmaceutical Industries Ltd, ONO Pharmaceutical Co., Ltd, Takeda Pharmaceutical Company Ltd, and Roche Group.
Ans: The active (symptomatic) multiple myeloma segment is expected to hold a higher market share in the Global Multiple Myeloma Market by type.
Ans: The immunomodulatory drugs segment is expected to hold the highest market share in the Global Multiple Myeloma Market by treatment.